Huang Shuaihao, Zhu Xiaowen, Ke Yuhong, Xiao Dan, Liang Changxiang, Chen Junfeng, Chang Yunbing
Department of Orthopedics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Cancer Biol Ther. 2020 Apr 2;21(4):379-387. doi: 10.1080/15384047.2019.1702405. Epub 2020 Jan 10.
It was well established that long non-coding RNAs (LncRNAs) could serve as oncogene or tumor suppressor in terms of the tumor type. FTX, as a member of lncRNA family, has been reported to be associated with several tumor progressions, such as hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and colorectal cancer. However, the regulatory role of FTX in osteosarcoma (OS) still lacks research analysis. This paper aims to explore how FTX exerts its regulatory role on OS by modulating TXNRD1/miR-320a, so as to provide a novel lncRNA theoretical framework for the diagnosis and treatment of OS. QRT-PCR revealed that FTX and TXNRD1 were abnormally upregulated in OS, whereas miR-320a expression was significantly decreased. Luciferase reporter analysis showed that both FTX and TXNRD1 could combine with miR-320a. A series of functional experiments indicated that knockdown of FTX could suppress OS cell proliferation and migration, while facilitating apoptosis ability simultaneously. However, TXNRD1 overexpression or miR-320a inhibition could rescue the oncogenic function of FTX. Taken all the experiment results together, this paper indicated that FTX impacted osteosarcoma cell proliferation and migration by modulating TXNRD1/miR-320a.
长期以来，人们已经明确，长链非编码RNA（LncRNAs）根据肿瘤类型可作为癌基因或肿瘤抑制因子。FTX作为lncRNA家族的一员，已被报道与多种肿瘤进展相关，如肝细胞癌（HCC）、肾细胞癌（RCC）和结直肠癌。然而，FTX在骨肉瘤（OS）中的调控作用仍缺乏研究分析。本文旨在探讨FTX如何通过调节TXNRD1/miR-320a对骨肉瘤发挥调控作用，从而为骨肉瘤的诊断和治疗提供一个新的lncRNA理论框架。定量逆转录聚合酶链反应（QRT-PCR）显示，FTX和TXNRD1在骨肉瘤中异常上调，而miR-320a表达显著降低。荧光素酶报告基因分析表明，FTX和TXNRD1均可与miR-320a结合。一系列功能实验表明，敲低FTX可抑制骨肉瘤细胞增殖和迁移，同时促进其凋亡能力。然而，TXNRD1过表达或miR-320a抑制可挽救FTX的致癌功能。综合所有实验结果，本文表明FTX通过调节TXNRD1/miR-320a影响骨肉瘤细胞的增殖和迁移。
